{"protocolSection":{"identificationModule":{"nctId":"NCT03840174","orgStudyIdInfo":{"id":"V160-003"},"secondaryIdInfos":[{"id":"V160-003","type":"OTHER","domain":"Merck Protocol Number"},{"id":"194648","type":"REGISTRY","domain":"JAPIC-CTI"}],"organization":{"fullName":"Merck Sharp & Dohme LLC","class":"INDUSTRY"},"briefTitle":"Safety and Immunogenicity of the Human Cytomegalovirus (CMV) Vaccine (V160) in Healthy Japanese Men (V160-003)","officialTitle":"A Phase I Randomized, Double-Blind, Placebo-controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of V160 (Human Cytomegalovirus Vaccine) in Healthy Japanese Men"},"statusModule":{"statusVerifiedDate":"2023-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2019-03-08","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2019-11-07","type":"ACTUAL"},"completionDateStruct":{"date":"2019-11-07","type":"ACTUAL"},"studyFirstSubmitDate":"2019-02-12","studyFirstSubmitQcDate":"2019-02-12","studyFirstPostDateStruct":{"date":"2019-02-15","type":"ACTUAL"},"resultsFirstSubmitDate":"2021-10-15","resultsFirstSubmitQcDate":"2021-10-15","resultsFirstPostDateStruct":{"date":"2021-11-15","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-05-04","lastUpdatePostDateStruct":{"date":"2023-05-06","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Merck Sharp & Dohme LLC","class":"INDUSTRY"}},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":true},"descriptionModule":{"briefSummary":"The purpose of the study is to assess the safety and tolerability of a 3-dose regimen of V160 administered by intramuscular (IM) injection in healthy Japanese male participants by cytomegalovirus (CMV) serostatus. There is no formal hypothesis."},"conditionsModule":{"conditions":["Cytomegalovirus Infections"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"TRIPLE","whoMasked":["PARTICIPANT","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":18,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"V160","type":"EXPERIMENTAL","description":"Participants will receive V160 vaccination by IM injection on Day 1, Month 2, and Month 6.","interventionNames":["Biological: V160"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"Participants will receive placebo by IM injection on Day 1, Month 2, and Month 6.","interventionNames":["Other: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"V160","description":"V160 administered as a 0.5 mL (100 Units) IM injection containing 225 mcg aluminum phosphate adjuvant (APA)","armGroupLabels":["V160"]},{"type":"OTHER","name":"Placebo","description":"Saline solution (0.9% sodium chloride \\[NaCl\\] administered as a 0.5 mL IM injection","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Percentage of Participants With a Solicited Injection-site Adverse Event (AE)","description":"Participants used the vaccination report card (VRC) to document the presence of any solicited injection-site AEs (pain/tenderness, erythema/redness, and swelling) that occurred in the 5 days after each vaccination. The percentage of participants with a solicited injection-site AE was reported.","timeFrame":"Up to 5 days after each vaccination"},{"measure":"Percentage of Participants With a Solicited Systemic Adverse Event (AE)","description":"Participants used the vaccination report card (VRC) to document the presence of any solicited systemic AEs (headache, fatigue, muscle pain, joint pain) that occurred in the 14 days after each vaccination. The percentage of participants with a solicited systemic AE is reported.","timeFrame":"Up to 14 days after each vaccination"},{"measure":"Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)","description":"An SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical event. The percentage of participants with an SAE considered to be at least possibly related to the study intervention will be reported","timeFrame":"Up to 14 days after each vaccination"}],"secondaryOutcomes":[{"measure":"Geometric Mean Titer (GMT) of CMV-specific Neutralizing Antibody (NAb)","description":"The NAb GMT in initially CMV-seronegative participants vaccinated with a 3-dose regimen of V160 administered IM was assessed.","timeFrame":"1 month after third vaccination (at 7 months)"},{"measure":"Number of Participants With Viral Detection of V160 in Plasma","description":"The number of participants with positive viral detection in plasma (defined by viral load in plasma ≥assay defined threshold cutoff value) was assessed.","timeFrame":"Day 1 (predose, at dosing, and 3 hours postdose), Day 3, Day 7, and Day 14"},{"measure":"Number of Participants With Wild-Type CMV Detection in Urine and Saliva","description":"The number of participants with positive wild-type viral shedding in urine or saliva (defined by viral load in saliva/urine ≥ assay defined threshold cutoff value) will be assessed.","timeFrame":"Day 1 (predose), 3, 7, and 14 and Months 2, 6, and 7"},{"measure":"Number of Participants With Viral Detection of V160 in Injection-site Swab and Adhesive Tape Swab","description":"The number of participants with positive viral leakage in injection-site swab and adhesive tape swab (defined by viral load in injection-site swab/adhesive tape swab ≥ assay defined threshold cutoff value) will be assessed.","timeFrame":"Day 1: 0, 10, 20, and 30 minutes postvaccination"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Healthy based on medical history and physical examination\n* Serologically confirmed to be CMV seropositive or CMV seronegative at Visit 1\n* If of reproductive potential, agrees to the following from randomization through at least 4 weeks after the last dose of V160-/placebo (from Day 1 through Month 7): 1) practice abstinence from heterosexual activity and remain abstinent, or 2) use contraception unless confirmed to be azoospermic as detailed in the protocol\n\nExclusion Criteria:\n\n* History of any allergic reaction or anaphylactic reaction to any vaccine component that required medical intervention\n* Plans donation of sperm any time from signing the informed consent through 1 month after receiving the last dose of study drug\n* Is currently immunocompromised or has been diagnosed as having a congenital or acquired immunodeficiency, human immunodeficiency virus (HIV) infection, lymphoma, leukemia, systemic lupus erythematosus, rheumatoid arthritis, juvenile rheumatoid arthritis, inflammatory bowel disease, or other autoimmune condition that requires immunosuppressive medication.\n* Has a condition in which repeated venipuncture or injections post more than minimal risk for the participant, such as hemophilia, thrombocytopenia, other severe coagulation disorders, or significantly impaired venous access\n* Has major psychiatric illness including: any history or schizophrenia or severe psychosis, bipolar disorder requiring therapy, or suicidal ideation within 3 years.\n* Has previously received any CMV vaccine\n* Had any live virus vaccine administered or scheduled to be administered in the period from 4 weeks prior to, and 4 weeks following receipt of study drug\n* Had any inactivated vaccine administered or scheduled within the period from 14 days prior to, through 14 days following study drug\n* Had administration of any immune globulin or blood product within 90 days prior to injection with study drug or scheduled within 30 days thereafter\n* Has received systemic corticosteroids (equivalent of ≥2 mg/kg total daily dose of prednisone or ≥20 mg/d for persons weighing \\>10 kg) for ≥14 consecutive days and has not completed treatment at least 30 days prior to study entry\n* Has received systemic corticosteroids exceeding physiologic replacement doses (≈5 mg/d prednisone equivalent) within 14 days prior to the first vaccination (participants using inhaled, nasal, or topical steroids are considered eligible for the study)\n* Has received any anti-viral agent (e.g. letermovir, ganciclovir, valganciclovir, foscarnet, and valacyclovir) with proven or potential activity against CMV 14 days prior to vaccination or is likely to receive such an agent within 14 days after vaccination\n\n  * Receiving or has received in the year prior to enrollment immunosuppressive therapies including but not limited to rapamycin (also sirolimus), tacrolimus (also FK-506), or other therapies used for solid organ/cell transplant, radiation therapy, immunosuppressive/cytotoxic immunotherapy, chemotherapy and other immunosuppressive therapies known to interfere with the immune response. Topical tacrolimus is allowed provided that it is not used within 14 days prior to, or 14 days following study drug\n* Has participated in another clinical trial in the past 4 weeks, or plans to participate in a treatment-based trial or a trial in which an invasive procedure is to be performed while enrolled in this trial.","healthyVolunteers":true,"sex":"MALE","genderBased":true,"genderDescription":"Healthy Japanese male participants between the ages of 20 and 64 (inclusive)","minimumAge":"20 Years","maximumAge":"64 Years","stdAges":["ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Merck Sharp & Dohme LLC","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Souseikai PS Clinic ( Site 0001)","city":"Fukuoka","zip":"812-0025","country":"Japan","geoPoint":{"lat":33.6,"lon":130.41667}}]},"referencesModule":{"references":[{"pmid":"36975369","type":"RESULT","citation":"Murata S, Oshima N, Iwasa T, Fukao Y, Sawata M. Safety, Tolerability, and Immunogenicity of V160, a Conditionally Replication-Defective Cytomegalovirus Vaccine, in Healthy Japanese Men in a Randomized, Controlled Phase 1 Study. Antibodies (Basel). 2023 Mar 10;12(1):22. doi: 10.3390/antib12010022."}]},"ipdSharingStatementModule":{"ipdSharing":"YES","description":"http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf","url":"http://engagezone.msd.com/ds_documentation.php"}},"resultsSection":{"participantFlowModule":{"recruitmentDetails":"Healthy male participants 20 to 64 years of age were recruited at study sites in Japan.","groups":[{"id":"FG000","title":"V160: CMV Seronegative at Baseline","description":"Participants who were cytomegalovirus (CMV)-seronegative at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"FG001","title":"V160: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"FG002","title":"Placebo: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."},{"id":"FG003","title":"Placebo: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Vaccination 1","achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Vaccination 2","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"Vaccination 3","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"6"},{"groupId":"FG002","numSubjects":"3"},{"groupId":"FG003","numSubjects":"3"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}],"dropWithdraws":[{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"V160: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"BG001","title":"Placebo: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."},{"id":"BG002","title":"V160: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"BG003","title":"Placebo: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."},{"id":"BG004","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"18"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"44.8","spread":"16.4"},{"groupId":"BG001","value":"36.3","spread":"16.0"},{"groupId":"BG002","value":"33.8","spread":"11.5"},{"groupId":"BG003","value":"24.7","spread":"5.5"},{"groupId":"BG004","value":"36.4","spread":"14.3"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"18"}]}]}]},{"title":"Ethnicity (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Hispanic or Latino","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Not Hispanic or Latino","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"18"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]},{"title":"Race (NIH/OMB)","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"American Indian or Alaska Native","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Asian","measurements":[{"groupId":"BG000","value":"6"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"18"}]},{"title":"Native Hawaiian or Other Pacific Islander","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Black or African American","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"White","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"More than one race","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]},{"title":"Unknown or Not Reported","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants With a Solicited Injection-site Adverse Event (AE)","description":"Participants used the vaccination report card (VRC) to document the presence of any solicited injection-site AEs (pain/tenderness, erythema/redness, and swelling) that occurred in the 5 days after each vaccination. The percentage of participants with a solicited injection-site AE was reported.","populationDescription":"All randomized participants who received at least 1 vaccination","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 5 days after each vaccination","groups":[{"id":"OG000","title":"V160: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG001","title":"V160: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG002","title":"Placebo: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."},{"id":"OG003","title":"Placebo: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0"},{"groupId":"OG001","value":"83.3"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"33.3"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Solicited Systemic Adverse Event (AE)","description":"Participants used the vaccination report card (VRC) to document the presence of any solicited systemic AEs (headache, fatigue, muscle pain, joint pain) that occurred in the 14 days after each vaccination. The percentage of participants with a solicited systemic AE is reported.","populationDescription":"All randomized participants who received at least 1 vaccination","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 14 days after each vaccination","groups":[{"id":"OG000","title":"V160: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG001","title":"V160: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG002","title":"Placebo: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."},{"id":"OG003","title":"Placebo: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"16.7"},{"groupId":"OG002","value":"33.3"},{"groupId":"OG003","value":"66.7"}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants With a Vaccine-related Serious Adverse Event (SAE)","description":"An SAE is defined as any untoward medical occurrence that, at any dose, results in death; is life-threatening; requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; is a congenital anomaly/birth defect; or other important medical event. The percentage of participants with an SAE considered to be at least possibly related to the study intervention will be reported","populationDescription":"All randomized participants who received at least 1 vaccination","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"Percentage of participants","timeFrame":"Up to 14 days after each vaccination","groups":[{"id":"OG000","title":"V160: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG001","title":"V160: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG002","title":"Placebo: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."},{"id":"OG003","title":"Placebo: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0"},{"groupId":"OG001","value":"0.0"},{"groupId":"OG002","value":"0.0"},{"groupId":"OG003","value":"0.0"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Titer (GMT) of CMV-specific Neutralizing Antibody (NAb)","description":"The NAb GMT in initially CMV-seronegative participants vaccinated with a 3-dose regimen of V160 administered IM was assessed.","populationDescription":"All randomized participants who were CMV-seronegative at baseline, received all 3 vaccinations, and did not deviate from the protocol in ways that could affect the immune response","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Geometric Mean Titer","timeFrame":"1 month after third vaccination (at 7 months)","groups":[{"id":"OG000","title":"V160: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG001","title":"Placebo: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"3"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3651","lowerLimit":"1688","upperLimit":"7895"},{"groupId":"OG001","value":"NA","lowerLimit":"NA","upperLimit":"115","comment":"Values below the lower limit of titer (\\<94) are represented by NA."}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"GMT Ratio","paramValue":"77.7","ciPctValue":"95","ciNumSides":"TWO_SIDED","ciLowerLimit":"23.9","ciUpperLimit":"252.4","estimateComment":"Geometric Mean Titer (GMT) ratio and 95% CI were estimated using an ANOVA model."}]},{"type":"SECONDARY","title":"Number of Participants With Viral Detection of V160 in Plasma","description":"The number of participants with positive viral detection in plasma (defined by viral load in plasma ≥assay defined threshold cutoff value) was assessed.","populationDescription":"All randomized participants who received at least one vaccination","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 (predose, at dosing, and 3 hours postdose), Day 3, Day 7, and Day 14","groups":[{"id":"OG000","title":"V160: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG001","title":"V160: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG002","title":"Placebo: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."},{"id":"OG003","title":"Placebo: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]}],"classes":[{"title":"Day 1 (predose)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"0 min postdose in Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"3 hr postdose in Day 1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Day 3 postdose","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Day 7 postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Day 14 postdose","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Wild-Type CMV Detection in Urine and Saliva","description":"The number of participants with positive wild-type viral shedding in urine or saliva (defined by viral load in saliva/urine ≥ assay defined threshold cutoff value) will be assessed.","populationDescription":"All randomized participants who received at least one vaccination","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1 (predose), 3, 7, and 14 and Months 2, 6, and 7","groups":[{"id":"OG000","title":"V160: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG001","title":"V160: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG002","title":"Placebo: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."},{"id":"OG003","title":"Placebo: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]}],"classes":[{"title":"Day 1 (predose)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Day 3 (postdose [PD] 1)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Day 7 (PD1)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Day 14 (PD1)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Month 2 (predose 2)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Month 6 (predose 3)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Month 7 (PD3)","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Viral Detection of V160 in Injection-site Swab and Adhesive Tape Swab","description":"The number of participants with positive viral leakage in injection-site swab and adhesive tape swab (defined by viral load in injection-site swab/adhesive tape swab ≥ assay defined threshold cutoff value) will be assessed.","populationDescription":"All randomized participants who received at least one vaccination","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"Day 1: 0, 10, 20, and 30 minutes postvaccination","groups":[{"id":"OG000","title":"V160: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG001","title":"V160: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant."},{"id":"OG002","title":"Placebo: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."},{"id":"OG003","title":"Placebo: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received placebo by IM injection on Day 1, Month 2, and Month 6."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"}]}],"classes":[{"title":"Swab from injection-site - 0 min PD1","categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Swab from injection-site - 10 min PD1","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Swab from injection-site - 20 min PD1","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Swab from injection-site - 30 min PD1","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Swab from adhesive tape (inside) - 10 min PD1","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Swab from adhesive tape (inside) - 20 min PD1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Swab from adhesive tape (inside) - 30 min PD1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Swab from adhesive tape (outside) - 10 min PD1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Swab from adhesive tape (outside) - 20 min PD1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]},{"title":"Swab from adhesive tape (outside) - 30 min PD1","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"0","timeFrame":"Up to 14 days post each vaccination for AE/SAE, and up to 6.5 months for all-cause mortality.","description":"All randomized participants who received at least one vaccination are included in safety analysis.","eventGroups":[{"id":"EG000","title":"V160: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":6,"otherNumAtRisk":6},{"id":"EG001","title":"V160: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received V160 vaccination by IM injection on Day 1, Month 2, and Month 6. V160 was administered as a 100-unit dose, with aluminum phosphate adjuvant.","deathsNumAffected":0,"deathsNumAtRisk":6,"seriousNumAffected":0,"seriousNumAtRisk":6,"otherNumAffected":5,"otherNumAtRisk":6},{"id":"EG002","title":"Placebo: CMV Seronegative at Baseline","description":"Participants who were CMV-seronegative at baseline received placebo by IM injection on Day 1, Month 2, and Month 6.","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":1,"otherNumAtRisk":3},{"id":"EG003","title":"Placebo: CMV Seropositive at Baseline","description":"Participants who were CMV-seropositive at baseline received placebo by IM injection on Day 1, Month 2, and Month 6.","deathsNumAffected":0,"deathsNumAtRisk":3,"seriousNumAffected":0,"seriousNumAtRisk":3,"otherNumAffected":2,"otherNumAtRisk":3}],"otherEvents":[{"term":"Diarrhoea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":6},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":3},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Injection site erythema","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":5,"numAffected":3,"numAtRisk":6},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Injection site pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":10,"numAffected":4,"numAtRisk":6},{"groupId":"EG001","numEvents":8,"numAffected":5,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":2,"numAffected":1,"numAtRisk":3}]},{"term":"Injection site swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":6},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Seasonal allergy","organSystem":"Immune system disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Myalgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":3}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 22.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":6},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":6},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":3},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":3}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results."},"pointOfContact":{"title":"Senior Vice President, Global Clinical Development","organization":"Merck Sharp & Dohme Corp.","email":"ClinicalTrialsDisclosure@merck.com","phone":"1-800-672-6372"}}},"documentSection":{"largeDocumentModule":{"largeDocs":[{"typeAbbrev":"Prot_SAP","hasProtocol":true,"hasSap":true,"hasIcf":false,"label":"Study Protocol and Statistical Analysis Plan","date":"2018-11-19","uploadDate":"2021-10-15T18:16","filename":"Prot_SAP_000.pdf","size":968401}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D003586","term":"Cytomegalovirus Infections"}],"ancestors":[{"id":"D006566","term":"Herpesviridae Infections"},{"id":"D004266","term":"DNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D007239","term":"Infections"}]}},"hasResults":true}